Testing of Toltrox 2.5% in experimental nosematosis of bees

In this study investigated the effectiveness and safety of Toltrox 2.5% against nosema disease, one of the parasitic diseases in bees, under laboratory conditions. The research on the effectiveness and safety of Toltrox 2.5% against nosema disease in bees was conducted in two stages. In the first st...

Full description

Saved in:
Bibliographic Details
Main Authors: Nasimov Shukhrat, Azimova Dilafruz, Safarov Khurshid, Akramov Komiljon
Format: Article
Language:English
Published: EDP Sciences 2025-01-01
Series:BIO Web of Conferences
Online Access:https://www.bio-conferences.org/articles/bioconf/pdf/2025/32/bioconf_esdca2025_02003.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study investigated the effectiveness and safety of Toltrox 2.5% against nosema disease, one of the parasitic diseases in bees, under laboratory conditions. The research on the effectiveness and safety of Toltrox 2.5% against nosema disease in bees was conducted in two stages. In the first stage, experiments were carried out to assess the tolerance of different doses of the drug in healthy bees, and the results were obtained. According to the research findings, Toltrox 2.5% did not exhibit toxic effects on the bee organism and was found to be safe when administered with sugar syrup. In the second stage, bees were infected with nosema disease, and the therapeutic efficacy of the drug was evaluated in scientific studies. The results of the experiments determined that the optimal doses of the drug were 0.25 ml and 0.5 ml of Toltrox 2.5% per 1 liter of sugar syrup, which helped eliminate Nosema spores and restore the physiological condition of the bees. The control group did not receive the drug and remained untreated, and by the 6th day, the bees in this group had perished. The obtained results confirm the effectiveness of Toltrox 2.5% as a protozoicidal agent and demonstrate its potential application in beekeeping for the prevention and treatment of nosema disease.
ISSN:2117-4458